Stella Therapeutics, a privately held drug discovery company, is developing first-in-class small molecules that hold the promise of curing Glioblastoma Multiforme (GBM), the most common and deadliest malignant brain tumor, while maintaining patient quality of life.
Stella Therapeutics is developing novel small molecules (ST drugs) that hold the promise of treating malignant tumors through a unique mechanism of action by initially blocking the migration and proliferation of tumor cells, and then selectively killing them through the induction of apoptosis (programmed cell death).
Glioblastoma multiforme (GBM or grade IV astrocytoma) is Stella Therapeutics first indication. GBMs are the most common and aggressive brain tumor, accounting for more then 60% of diagnosed brain tumors in adults yet no cure is available for these patients. Thus there is an urgent need for novel therapeutics that will safely treat patients diagnosed with GBM.